Sustained Antiretroviral Effect of Raltegravir After 96 Weeks of Combination Therapy in Treatment-Naive Patients With HIV-1 Infection-Reference-Cited by-同舟云学术

Sustained Antiretroviral Effect of Raltegravir After 96 Weeks of Combination Therapy in Treatment-Naive Patients With HIV-1 Infection

Published:2009-11 Issue:3 Volume:52 Page:350-356
ISSN:1525-4135
Container-title:JAIDS Journal of Acquired Immune Deficiency Syndromes
language:en
Short-container-title:

Author:

Markowitz Martin,Nguyen Bach-Yen,Gotuzzo Eduardo,Mendo Fernando,Ratanasuwan Winai,Kovacs Colin,Prada Guillermo,Morales-Ramirez Javier O,Crumpacker Clyde S,Isaacs Robin D,Campbell Havilland,Strohmaier Kim M,Wan Hong,Danovich Robert M,Teppler Hedy

Publisher

Ovid Technologies (Wolters Kluwer Health)

Subject

Pharmacology (medical),Infectious Diseases

Reference9 articles.

1. Inhibitors of strand transfer that prevent integration and inhibit HIV-1 replication in cells.;Hazuda;Science,2000

2. Safety and efficacy of the HIV-1 integrase inhibitor raltegravir (MK-0518) in treatment-experienced patients with multidrug-resistant virus: a phase II randomized controlled trial.;Grinsztejn;Lancet,2007

3. Raltegravir with optimized background therapy for resistant HIV-1 infection.;Steigbigel;N Eng J Med,2008

4. Subgroup and resistance analyses of raltegravir for resistant HIV-1 infection.;Cooper;N Eng J Med,2008

5. Rapid and durable antiretroviral effect of the HIV-1 integrase inhibitor raltegravir as part of combination therapy in treatment-naive patients with HIV-1 infection: results of a 48-week controlled study.;Markowitz;J Acquir Immune Defic Syndr,2007

Cited by 103 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. A Pharmacokinetic Dose-Optimization Study of Cabotegravir and Bictegravir in a Mouse Pregnancy Model;Pharmaceutics;2022-08-24

2. Initial Antiretroviral Therapy in an Integrase Inhibitor Era;Infectious Disease Clinics of North America;2019-09

3. A model-based comparative meta-analysis of the efficacy of dolutegravir-based and efavirenz-based regimens in HIV-infected patients;Journal of Infection and Chemotherapy;2019-09

4. Long-term tolerability and effectiveness of raltegravir in Japanese patients: Results from post-marketing surveillance;PLOS ONE;2019-01-09

5. Co-treatment of Tuberculosis and HIV: Pharmacologic Considerations;HIV and Tuberculosis;2019